Document Detail

Androgen Receptor Activation in Castration-Recurrent Prostate Cancer: The Role of Src-Family and Ack1 Tyrosine Kinases.
Jump to Full Text
MedLine Citation:
PMID:  24948875     Owner:  NLM     Status:  Publisher    
There is growing appreciation that castration-recurrent prostate cancer (CR-CaP) is driven by the continued expression of androgen receptor (AR). AR activation in CR-CaP through various mechanisms, including AR overexpression, expression of AR splice variants or mutants, increased expression of co-regulator proteins, and by post-translational modification, allows for the induction of AR-regulated genes in response to very low levels of tissue-expressed, so-called intracrine androgens, resulting in pathways that mediate CaP proliferation, anti-apoptosis and oncogenic aggressiveness. The current review focuses on the role played by Src-family (SFK) and Ack1 non-receptor tyrosine kinases in activating AR through direct phosphorylation, respectively, on tyrosines 534 or 267, and how these modifications facilitate progression to CR-CaP. The fact that SFK and Ack1 are central mediators for multiple growth factor receptor signaling pathways that become activated in CR-CaP, especially in the context of metastatic growth in the bone, has contributed to recent therapeutic trials using SFK/Ack1 inhibitors in monotherapy or in combination with antagonists of the AR activation axis.
Irwin H Gelman
Related Documents :
23454015 - Triazolopyridazine lrrk2 kinase inhibitors.
25005755 - A novel agent with histone deacetylase inhibitory activity attenuates neointimal hyperp...
9514945 - Camp enhances csf-1-induced erk activity and c-fos mrna expression via a mek-dependent ...
24033945 - Erk signaling mediates enhanced angiotensin ii-induced rat aortic constriction followin...
7987735 - Time-dependent effects of parathyroid hormone and prostaglandin e2 on dna synthesis by ...
24599075 - P62/sqstm1 accumulation in squamous cell carcinoma of head and neck predicts sensitivit...
Publication Detail:
Type:  REVIEW     Date:  2014-6-5
Journal Detail:
Title:  International journal of biological sciences     Volume:  10     ISSN:  1449-2288     ISO Abbreviation:  Int. J. Biol. Sci.     Publication Date:  2014  
Date Detail:
Created Date:  2014-6-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101235568     Medline TA:  Int J Biol Sci     Country:  -    
Other Details:
Languages:  ENG     Pagination:  620-626     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Int J Biol Sci
Journal ID (iso-abbrev): Int. J. Biol. Sci
Journal ID (publisher-id): ijbs
ISSN: 1449-2288
Publisher: Ivyspring International Publisher, Sydney
Article Information
Download PDF
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License ( Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
Received Day: 2 Month: 12 Year: 2013
Accepted Day: 6 Month: 1 Year: 2014
collection publication date: Year: 2014
Electronic publication date: Day: 5 Month: 6 Year: 2014
Volume: 10 Issue: 6
First Page: 620 Last Page: 626
PubMed Id: 24948875
ID: 4062955
DOI: 10.7150/ijbs.8264
Publisher Id: ijbsv10p0620

Androgen Receptor Activation in Castration-Recurrent Prostate Cancer: The Role of Src-Family and Ack1 Tyrosine Kinases
Irwin H. Gelman✉
Department of Cancer Genetics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Correspondence: ✉ Corresponding author: Tel: 716-845-7681 Fax: 716-845-1698
[conflict] Competing Interests: The authors have declared that no competing interest exists.


In 2013, 238,590 new cases of prostate cancer (CaP) are estimated to be identified, typically through increased levels of serum prostate specific antigen (PSA), digital rectal exams and pathologic analyses of biopsy samples. Roughly 12-13% of these cases will result in death (29,720 estimated in 2013), making it the second leading cause of cancer deaths in U.S. men ( Since the initial description by Huggins and Hodges in 1941 1 that CaP can be clinically reduced by castration, which causes deprivation of testicular androgen, most treatment-naïve CaP cases have been treated with some combination of androgen-deprivation therapy (ADT) plus surgical prostatectomy or radio-ablation. This has resulted in high initial cure rates of early, localized disease and palliation of metastatic disease. However, the so-called lethal clinical phenotype of CaP relates to disease recurrence following ADT, producing castration-recurrent (CR) metastatic disease that is found primarily in the bones and lymph nodes, and that responds poorly to standard chemotherapy and radiation 2.

CR-CaP: Dependence on AR signaling

Most CR-CaP cases continue to express the androgen receptor (AR) as well as significant androgen- and AR-driven genes such as PSA 3. Indeed, CR-CaP cases typically express increased levels of AR protein 4-6, sometimes attributable to AR gene amplification 7, and as well, increased levels of androgen-responsive genes such as PSA and TMPRSS2 8. The notion that CR-CaP is AR-dependent is supported by the recent clinical success of AR antagonists such as enzalutamide (MDV3100), which increases survival rates in CR-CaP patients but only for several months 9. The ultimate failure of AR antagonists to produce durable cures has been associated with the generation of AR splice variants lacking the ligand-binding domain (LBD) 10 or a F876L mutation in the LBD 11, 12. Less understandable, however, are enzalutamide-resistant cases that continue to express WT-AR; these may reflect that AR overexpression may convert AR antagonists to agonists 13. In addition to AR activation by direct tyrosine phosphorylation by SFK and Ack1 kinases- which will be the focus of the current review, other studies have identified additional AR-related changes that may contribute to CR-CaP: i) AR mutations (primarily in the LBD) that increase binding for non-androgen agonists 14, ii) AR stabilization 15, iii) induction of AR co-regulators and iv) post-translational modification 14. These CR-associated changes are thought to facilitate AR-driven tumor progression in response to the post-castration expression of low levels tissue androgens 16.

The notion that the sustained expression of AR-driven genes is required for CR-CaP generation is supported by several studies using mouse models of human CaP. For example, Yuan et al. 17 showed that growth of a cell line (R3) derived from CR-growths of the human CWR22 xenograft in castrates was suppressed by the shRNA-mediated knockdown of AR, even though growth was not inhibited by the anti-androgen, bicalutimide. Campagno et al. 18 showed that intratumoral injections of AR-siRNA inhibited growth of LNCaP-C4-2 and CWR22Rv1 cells, two CR-CaP lines. Similar findings were demonstrated by Snoek et al. 19 using a tetracycline-regulated AR-shRNA in LNCaP-C4-2 cells and by Guo et al. 20 using AR-shRNA in CWR22Rv1 cells in castrates. An interesting twist on this concept comes from the study of Gan et al., 21, who showed that the ability of paclitaxel to inhibit the CR growth of CWR22Rv1 cells correlated with the downregulation of AR caused by the expression of the PTEN tumor suppressor and the nuclear accumulation of the AR suppressive transcription factor, FOXO1. Thus, siRNA-mediated FOXO1 knockdown attenuated the inhibitory effect of paclitaxel on AR-driven CR-promoting genes.

Several studies have demonstrated that androgen-independent or CR-CaP cell lines, or CR-CaP tumor samples, have AR-driven gene expression signatures that correlate with CR-CaP. Work from the Chinnaiyan and Brown labs 22, 23 used AR-ChIP-chip or -ChIP-seq combined with gene expression analyses to identify AR cistrome genes in an androgen-independent LNCaP variant cell line whose expression pattern correlated with CR disease in humans. For example, the study of Wang et al. 23 identified UBE2C, an AR-driven cell cycle regulated gene that overrides an M-phase checkpoint, as a marker of androgen-independent growth. Interestingly, by comparing the AR cistrome in CaP cells expressing full-length (FL) AR vs. a splice variant (V) of AR typically upregulated in abiraterone and enzalutamide-resistant CR-CaP cells and tumors, Hu et al. 24 also identified UBE2C expression as a marker of specific for CR-CaP. A more recent study by Sharma et al. 25 analyzed the AR cistrome in human clinical CR-CaP samples, identifying a 16-gene signature with stronger correlation to CR-CaP than the aforementioned Chinnaiyan and Brown lab studies. Importantly, these and other studies identified transcription factors such as GATA, OCT, PU1, TEF1 26, FOXA1 25, and the methyltransferase, EZH2 27 as potential AR co-factors based on the proximity of their ChIP sites with those of AR. Some transcriptional co-factors, such as FOXA1, may only play a role in ligand-dependent AR function, since androgen-independent AR binding sites in CR-CaP, whose sequences increasingly diverge from the classic androgen responsive element (ARE: 5'-GGA/TACANNNTGTTCT-3'; 28), form under conditions of FOXA1-independence 29.

CR-CaP: Increased Protein Tyrosine Phosphorylation, SFK and Ack1 activity

The regulation of AR transcriptional activity by post-translational modifications such as phosphorylation, acetylation, sumoylation, ubiquitination and methylation, have been well described 30. CR-CaP clinical samples exhibit increased relative protein tyrosine phosphorylation levels compared to levels in AD-CaP 31. This correlates with increased activation levels on non-receptor tyrosine kinases 32 as well as receptor tyrosine kinases such as Met 33, c-Kit 34 and the EGFR family 35, 36. However, the role of AR tyrosine phosphorylation may have been underappreciated because it is not induced by androgens such as dihydrotestosterone (DHT), whereas it is induced by EGF, heregulin, IL-6 or serum 20, 37, 38. In contrast, androgens induce IGF-1R activity in prostate cancer progression 39.

Although Src-family kinases are rarely mutated in human cancers 40, 41, there is growing appreciation that they play critical roles in cancer progression, especially associated with recurrent and metastatic disease 42-45, due to gene amplification 46, overexpression or activation by post-translational modification (reviewed in 47). Indeed, SFK play central roles in mediating oncogenic signaling downstream of many receptor tyrosine kinases, which are themselves activated in cancer by multiple mechanisms 48. FGR is the only SFK member gene that has been shown to be amplified in prostate cancer, specifically, in 37% of hormone-refractory disease 49. In contrast, SFK members Src and Lyn are activated in CaP cell lines 50, 51 and tumor tissues 51, and Fyn is upregulated in primary prostate cancer vs. benign lesions 52, and even higher in metastases as evidenced by in silico analysis of Oncomine studies (Figure 1). Most SFK members share an autophosphorylation site (termed Y416 for chicken Src, Y419 for human Src) that is recognized by Src-poY416-specific antibodies and that is an appropriate surrogate marker for kinase activity in cells 53. A limited set of studies has demonstrated a ~2.5-fold increase in relative Src-poY416 staining in CR- vs. AD-CaP samples 20, 54, and in metastases (bone and lymph node) vs. primary tumor sites (Figure 2, unpublished data, Gary Gallick, MD Anderson Cancer Center). Taken together, these data strongly support a role for increased tyrosine kinase and SFK activity for progression to CR- and metastatic CaP.

In addition to the role of SFK in prostate cancer progression, several groups have reported that the non-receptor tyrosine kinase, Ack1 (Activated Cdc42-associated Kinase 1) may facilitate CaP progression through the direct activation of AR. Several mechanisms for Ack1 activation in prostate cancer have been identified, including gene amplification 55 or kinase hyperactivation 38 that occurs downstream of multiple receptor tyrosine kinases 56. As shown in the study of Taylor et al. 57 (Figure 3), increasing levels of Ack1 (TNK2) message are found in primary site CaP compared to normal or benign prostate hyperplasias (BPH), and even higher levels are found in lymph node metastases.

Several lines of evidence indicate that the expression of specific SFK or Ack1 can drive the formation of CaP or progression to CR-CaP. Although not the main focus of this review, there is a large body of evidence showing that SFK play key roles in facilitating proliferation of CaP induced by various growth factors and in promoting oncogenic migration parameters such as invasiveness 58 (reviewed in 32, 59). Indeed, Src is required for the lymph node metastasis of a metastatic variant of PC-3 CaP cells although its knockdown has no effect on primary tumor growth 58. Gelman et al. 60 recently demonstrated that TRAMP mice, whose prostate cancer progression is induced by the prostate-specific transgenic expression of the SV40 Tag 61, had greatly diminished prostatic adenocarcinoma and metastasis formation rates when crossed into Src-null, and to a lesser extent, Lyn-null backgrounds, but no change in the rate or extent of conversion to neuroendocrine cancer in the prostate. The loss of Fyn had no effect on primary tumor or metastasis formation in TRAMP mice exhibiting CaP. However, an interesting finding, and one that merits further investigation in the context of human disease, is that in rare cases where primary CaP failed to form within the typical onset period (<20 weeks of age), the loss of Src, Lyn or Fyn resulted in highly aggressive metastatic disease exhibiting markers of adenocarcinoma. This might suggest that SFK suppress the growth of metastases in the absence of paracrine factors secreted by primary tumors, a phenomenon described in the TRAMP model 62 and in human cancers 63.

The notion that activated Src is sufficient to drive CaP initiation comes from the study of Cai et al. 64 who used a tissue recombination model to show that Src, and to lesser extents, Fyn and Lyn, can induce prostatic basal epithelial cells to form CaP tumors when mixed with urogenital sinus mesenchymal cells. Subsequent phosphoproteome analyses of mouse tumors induced by activated AKT plus AR, ERG, or activated K-Ras, as well as of metastatic CR-CaP patient tumors, showed evidence of Src-driven pathways 31, 65. Interestingly, even the overexpression of non-mutated c-Src was able to induce CaP initiation in the context of AR overexpression 66, an important finding given that Src kinase-activating mutations are not readily found in primary or CR-CaP 67-69. A recent paper by Su et al. 70 demonstrates that the frequency and time-to-onset of spontaneously generated CR-CaP in the CWR22 xenograft model are decreased by the siRNA-mediated knockdown of Src.

Activation of AR by Direct Phosphorylation: Role of SFK and Ack1

The landmark study by Guo et al. 20 demonstrated that AR activation could be induced by direct phosphorylation by Src on Y534, as identified by mass spectrometry. Kraus et al. 71 confirmed that the Src-mediated tyrosine phosphorylation of AR was positively regulated by the PKC scaffolding protein, RACK1. The concept that AR might serve as a Src substrate is strengthened by evidence that a Src-AR complex is required for androgen-induced CaP cell proliferation in vitro72 and that Src kinase inhibition blocks AR-dependent transactivation of known androgen-inducible genes 20, 73. Moreover, expression of activated Src and the subsequent phosphorylation of AR on Y534 are sufficient to induce androgen-independent growth in vitro in LNCaP and LAPC-4 cells 38 and CR growth in vivo20. Activated Ack1 could also facilitate androgen-independent CaP cell proliferation in vitro through the direct phosphorylation of AR on Y267 38, 74. EGF treatment of LNCaP or LAPC-4 cells could induce AR phosphorylation on both Y267 and Y534, whereas other pro-proliferative stimulants could only activate AR through either Ack1 or Src pathways: AR-poY267 could be induced by heregulin or the Mer receptor ligand, Gas6, whereas AR-poY534 could be induced by IL-6 or bombesin 37. Importantly, increased AR-poY267 and -poY534 staining levels correlate with CR-CaP disease progression and worse survival prognosis 20, 75, strongly suggesting that the increased activation of SFK and Ack1, and subsequent AR activation through direct phosphorylation by these kinases, facilitates CaP malignancy, especially CR progression.

Several non-genotropic AR functions have been described and are thought to occur at the plasma membrane, i.e.- not through AR's transactivation function 76. Interestingly, Src may controls these functions, which are poorly understood but which may regulate cell survival pathways, by direct binding to AR 77, 78 although data are lacking as to whether this control axis is dependent on Src phosphorylation of AR.

Tyrosine Kinase Antagonist Treatment in CR-CaP

Studies corroborating the involvement of activated Src in progression to androgen-independence or castration-recurrence 70, 73, 79, 80, increased invasiveness 66, or metastatic growth in bones 81, as well as preclinical studies demonstrating critical roles for SFK in prostate cancer metastasis 51, 58, 82-85 have spawned clinical trials using SFK-specific or pan-tyrosine kinase inhibitors (reviewed in 2, 36). Indeed, a large set of review papers have addressed the rationale of targeting of SFK and Ack1 in CR-CaP, especially in its main manifestation as bone metastatic growths 36, 42, 43, 58, 86-90.

The effects of kinase inhibitors on CaP biology in vitro and in vivo depends, in most cases, on the specificity of the drugs studied. For example, Dasatinib (BMS-354825), originally described as a Src/Abl-specific inhibitor 91, likely inhibits a wide range of receptor- and non-receptor tyrosine kinases 92. Thus, whereas initial reports demonstrated that Dasatinib could inhibit Src/FAK-mediated signaling pathways that control prostate cancer cell adhesion, motility and invasiveness 50, 93, subsequent reports showed that it could also inhibit CaP growth as boney metastases 94, androgen-independent growth 54 associated with the site-specific tyrosine phosphorylation of AR by Src or Ack1 37, or spontaneous formation of CR (CWR22) tumors 70. Although early clinical trials showed some efficacy of using Dasatinib as a monotherapy or in combination with docetaxel 95-99, the recent READY Phase III trial showed that adding Dasatinib had no greater effect on survival in cases of chemotherapy-naïve metastatic CR-CaP 100. Importantly, serum markers, such as insulin-like growth factor-1 (IGF-1), have been identified that correlate with efficacy by Dasatinib in metastatic CR-CaP cases 101, prompting a study by Dayyani et al. 102 showing superior inhibition of CR-CaP growths in mouse models when combining the IGF-1receptor/insulin-receptor inhibitor, BMS-754807, with Dasatinib.

The argument that Dasatinib's broad tyrosine kinase specificity undercuts its clinical efficacy 103 has resulted in the increased focus on more specific SFK inhibitors in CR-CaP. For example, Saracatinib (AZD0530), a Src/Abl inhibitor which showed anti-CaP efficacy in preclinical CaP models 104, 105 and in PC-3 bone metastases 106, showed efficacy as a monotherapy in CR-CaP patients 107. Bosutinib (SKI-606) is another Src/Abl inhibitor 108 that has shown efficacy against prostate cancer in preclinical models 109, has passed Phase I testing 110 and was FDA-approved for use in Gleevec-resistant chronic myelogenous leukemia, yet is not part of any current Phase II trials for prostate cancer. Cabozantinib (XL184), an inhibitor of the Met receptor tyrosine kinase, which manifests its oncogenic signaling in prostate cancer through Src activation 83, has shown efficacy in Phase II trials against CR-CaP 111. KXO1 (KX2-391) is a novel non-ATP-competitive Src/tubulin polymerization inhibitor which, in recent Phase II studies 112, failed to reduce tumor burden in bone-metastasis CR-CaP cases, although a caveat noted was that the dosing was insufficient to achieve the drug's tubulin polymerization inhibition activity. Lastly, several new Ack1-specific inhibitors have been identified 113, including AIM-100, which has shown efficacy against CR-CaP cell lines in vitro and in vivo75, 114.

Future Directions

The growing corpus of evidence showing that SFK and Ack1 are potent drivers of CR-CaP and metastasis via AR-dependent mechanisms has led to a renewed focus on developing specific tyrosine kinase inhibitors as mainline or adjunct therapies. In addition to solving issues of increased toxicities when combining such antagonists with newer generation inhibitors of AR or androgen synthesis, such as enzalutamide or abiraterone, respectively, there is no consensus a priori as to whether SFK-specific drugs might work better than those with broad specificity for tyrosine kinases. As the use of SFK/Ack1 inhibitors increases in CR-CaP populations, one area needing improvement is the identification and development of bio- or genetic markers of drug efficacy. One such example might be the development of immunohistochemistry-grade antibodies specific for AR-poY267 and -poY534. Indeed, newer pharmacogenetic paradigms are being developed to identify individualized response and toxicity signatures that will help stratify patient-specific treatments 115 with the aim of improving patient survival outcomes.

1. Huggins C,Hodges CV,Studies on Prostatic Cancer: IThe Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the ProstateYear: 19411298307
2. George D,Moul JW,Emerging treatment options for patients with castration-resistant prostate cancerProstateYear: 20127233834921748753
3. Azzouni F,Mohler J,Biology of castration-recurrent prostate cancerUrol Clin North AmYear: 20123943545223084522
4. Sharifi N,Mechanisms of androgen receptor activation in castration-resistant prostate cancerEndocrinologyYear: 20131544010401724002034
5. Mohler JL,A role for the androgen-receptor in clinically localized and advanced prostate cancerBest Pract Res Clin Endocrinol MetabYear: 20082235737218471792
6. Schmidt LJ,Tindall DJ,Androgen receptor: past, present and futureCurr Drug TargetsYear: 20131440140723565753
7. El Gedaily A,Bubendorf L,Willi N,et al. Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridizationProstateYear: 20014618419011170146
8. Ryan CJ,Tindall DJ,Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeuticallyJ Clin OncolYear: 2011293651365821859989
9. Scher HI,Fizazi K,Saad F,et al. Increased survival with enzalutamide in prostate cancer after chemotherapyN Engl J MedYear: 20123671187119722894553
10. Li Y,Chan SC,Brand LJ,et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell linesCancer ResYear: 20137348348923117885
11. Joseph JD,Lu N,Qian J,et al. A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509Cancer DiscovYear: 201331020102923779130
12. Korpal M,Korn JM,Gao X,et al. An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)Cancer DiscovYear: 201331030104323842682
13. Chen CD,Welsbie DS,Tran C,et al. Molecular determinants of resistance to antiandrogen therapyNat MedYear: 200410333914702632
14. Lamont KR,Tindall DJ,Minireview: Alternative activation pathways for the androgen receptor in prostate cancerMol EndocrinolYear: 20112589790721436259
15. Gregory CW,Johnson RT Jr,Mohler JL,et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgenCancer ResYear: 2001612892289811306464
16. Mohler JL,Castration-recurrent prostate cancer is not androgen-independentAdv Exp Med BiolYear: 20086172233418497046
17. Yuan X,Li T,Wang H,et al. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cellsAm J PatholYear: 200616968269616877366
18. Compagno D,Merle C,Morin A,et al. SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomasPLoS OneYear: 20072e1006
19. Snoek R,Cheng H,Margiotti K,et al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumorsClin Cancer ResYear: 200915394719118031
20. Guo Z,Dai B,Jiang T,et al. Regulation of androgen receptor activity by tyrosine phosphorylationCancer CellYear: 20061030931917045208
21. Gan L,Chen S,Wang Y,et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancerCancer ResYear: 2009698386839419826044
22. Wang Q,Li W,Liu XS,et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growthMol CellYear: 20072738039217679089
23. Wang Q,Li W,Zhang Y,et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancerCellYear: 200913824525619632176
24. Hu R,Lu C,Mostaghel EA,et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancerCancer ResYear: 2012723457346222710436
25. Sharma NL,Massie CE,Ramos-Montoya A,et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in manCancer CellYear: 201323354723260764
26. Lin B,Wang J,Hong X,et al. Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptorPLoS OneYear: 20094e6589
27. Chng KR,Chang CW,Tan SK,et al. A transcriptional repressor co-regulatory network governing androgen response in prostate cancersEMBO JYear: 2012312810282322531786
28. Roche PJ,Hoare SA,Parker MG,A consensus DNA-binding site for the androgen receptorMol EndocrinolYear: 19926222922351491700
29. Decker KF,Zheng D,He Y,et al. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditionsNucleic Acids ResYear: 201240107651077923019221
30. Coffey K,Robson CN,Regulation of the androgen receptor by post-translational modificationsJ EndocrinolYear: 201221522123722872761
31. Drake JM,Graham NA,Stoyanova T,et al. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progressionProc Natl Acad Sci U S AYear: 20121091643164822307624
32. Chang YM,Kung HJ,Evans CP,Nonreceptor tyrosine kinases in prostate cancerNeoplasiaYear: 200799010017357254
33. Knudsen BS,Edlund M,Prostate cancer and the met hepatocyte growth factor receptorAdv Cancer ResYear: 200491316715327888
34. Paronetto MP,Farini D,Sammarco I,et al. Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancerAm J PatholYear: 20041641243125115039213
35. Lorenzo GD,Bianco R,Tortora G,et al. Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independenceClin Prostate CancerYear: 20032505715046685
36. Gallick GE,Corn PG,Zurita AJ,et al. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancerFuture Med ChemYear: 2012410711922168167
37. Liu Y,Karaca M,Zhang Z,et al. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinasesOncogeneYear: 2010293908391620440264
38. Mahajan NP,Liu Y,Majumder S,et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylationProc Natl Acad Sci U S AYear: 20071048438844317494760
39. 39Pandini G, Mineo R, Frasca F, et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cellsCancer ResYear: 2005651849185715753383
40. Frame MC,Newest findings on the oldest oncogene; how activated src does itJ Cell SciYear: 200411798999814996930
41. Irby RB,Mao WG,Coppola D,et al. Activating SRC mutation in a subset of advanced human colon cancersNature GenetYear: 1999211871909988270
42. Boyce B,Xing L,Src inhibitors in the treatment of metastatic bone disease: rationale and clinical dataClin Investig (Lond)Year: 2011116951706
43. Edwards J,Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancerExpert Opin Investig DrugsYear: 201019605614
44. Kim MP,Park SI,Kopetz S,et al. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasisCell Tissue ResYear: 200933524925918815812
45. Summy JM,Gallick GE,Src family kinases in tumor progression and metastasisCancer Metastasis RevYear: 20032233735812884910
46. Kiyose S,Nagura K,Tao H,et al. Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridizationPathol IntYear: 20126247748422691185
47. Gelman IH,Src-family tyrosine kinases as therapeutic targets in advanced cancerFront Biosci (Elite Ed)Year: 2011380180721622091
48. Wheeler DL,Iida M,Dunn EF,The role of Src in solid tumorsOncologistYear: 20091466767819581523
49. Edwards J,Krishna NS,Witton CJ,et al. Gene amplifications associated with the development of hormone-resistant prostate cancerClin Cancer ResYear: 200395271528114614009
50. Nam S,Kim D,Cheng JQ,et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cellsCancer ResYear: 2005659185918916230377
51. Goldenberg-Furmanov M,Stein I,Pikarsky E,et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenograftsCancer ResYear: 2004641058106614871838
52. Posadas EM,Al-Ahmadie H,Robinson VL,et al. FYN is overexpressed in human prostate cancerBJU IntYear: 200910317117718990162
53. Frame MC,Src in cancer: deregulation and consequences for cell behaviourBiochimica Et Biophysica Acta-Reviews On CancerYear: 20021602114130
54. Tatarov O,Mitchell TJ,Seywright M,et al. SRC family kinase activity is up-regulated in hormone-refractory prostate cancerClin Cancer ResYear: 2009153540354919447874
55. van der Horst EH,Degenhardt YY,Strelow A,et al. Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1Proc Natl Acad Sci U S AYear: 2005102159011590616247015
56. Mahajan K,Mahajan NP,ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferationCancer LettYear: 201333818519223597703
57. Taylor BS,Schultz N,Hieronymus H,et al. Integrative genomic profiling of human prostate cancerCancer CellYear: 201018112220579941
58. Park SI,Zhang J,Phillips KA,et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse modelCancer ResYear: 2008683323333318451159
59. Fizazi K,The role of Src in prostate cancerAnn OncolYear: 2007 doi: 10.1093/annonc/mdm086.
60. Gelman IH,Peresie J,Eng KH,et al. Differential requirement for Src-family tyrosine kinases for prostate cancer, initiation progression and metastasis in the TRAMP mouse modelMolecular Cancer ResearchYear: 2013 in press.
61. Kaplan-Lefko PJ,Chen TM,Ittmann MM,et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse modelProstateYear: 20035521923712692788
62. Kwon ED,Foster BA,Hurwitz AA,et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapyProc Natl Acad Sci U S AYear: 199996150741507910611340
63. Peeters CF,de Waal RM,Wobbes T,et al. Metastatic dormancy imposed by the primary tumor: does it exist in humans?Ann Surg OncolYear: 2008153308331518685897
64. Cai H,Smith DA,Memarzadeh S,et al. Differential transformation capacity of Src family kinases during the initiation of prostate cancerProc Natl Acad Sci U S AYear: 20111086579658421464326
65. Drake JM,Graham NA,Lee JK,et al. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targetsProc Natl Acad Sci U S AYear: 2013
66. Cai H,Babic I,Wei X,et al. Invasive prostate carcinoma driven by c-Src and androgen receptor synergyCancer ResYear: 20117186287221135112
67. Beltran H,Yelensky R,Frampton GM,et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneityEur UrolYear: 20136392092622981675
68. Kumar A,White TA,Mackenzie AP,et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancersProc Natl Acad Sci U S AYear: 2011108170871709221949389
69. Grasso CS,Wu YM,Robinson DR,et al. The mutational landscape of lethal castration-resistant prostate cancerNatureYear: 201248723924322722839
70. Su B,Gillard B,Gao L,et al. Src controls castration recurrence of CWR22 prostate cancer xenograftsCancer MedYear: 2013267849224403252
71. Kraus S,Gioeli D,Vomastek T,et al. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptorCancer ResYear: 200666110471105417108144
72. Migliaccio A,Varricchio L,De FA,et al. Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growthOncogeneYear: 2007266619662917486077
73. Asim M,Siddiqui IA,Hafeez BB,et al. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cellsOncogeneYear: 2008273596360418223692
74. Mahajan NP,Whang YE,Mohler JL,et al. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor WwoxCancer ResYear: 200565105141052316288044
75. Mahajan K,Challa S,Coppola D,et al. Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activityProstateYear: 2010701274128520623637
76. Yu J,Akishita M,Eto M,et al. Src kinase-mediates androgen receptor-dependent non-genomic activation of signaling cascade leading to endothelial nitric oxide synthaseBiochem Biophys Res CommunYear: 201242453854322771325
77. Kousteni S,Bellido T,Plotkin LI,et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activityCellYear: 200110471973011257226
78. Migliaccio A,Castoria G,Di Domenico M,et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferationEMBO JYear: 2000195406541711032808
79. Kung HJ,Evans CP,Oncogenic activation of androgen receptorUrol OncolYear: 200927485219111798
80. Asim M,Hafeez BB,Siddiqui IA,et al. Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinaseJ Biol ChemYear: 2011286371083711721856747
81. Putzke AP,Ventura AP,Bailey AM,et al. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinasesAm J PatholYear: 201117940041021703419
82. Inoue S,Branch CD,Gallick GE,et al. Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cellsMol TherYear: 20051270771516054437
83. Kim SJ,Johnson M,Koterba K,et al. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse modelClin Cancer ResYear: 200395161517014613995
84. Putzke AP,Ventura AP,Bailey AM,et al. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinasesAm J PatholYear: 201117940041021703419
85. Yano A,Tsutsumi S,Soga S,et al. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in boneProc Natl Acad Sci U S AYear: 2008105155411554618840695
86. Agarwal N,Sonpavde G,Sternberg CN,Novel Molecular Targets for the Therapy of Castration-Resistant Prostate CancerEur UrolYear: 20126159506022209376
87. Rove KO,Crawford ED,Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survivalOncology (Williston Park)Year: 201125136281 1387. 22329188
88. Saad F,Src as a therapeutic target in men with prostate cancer and bone metastasesBJU IntYear: 200910343444019154462
89. Saad F,Lipton A,SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancerCancer Treat RevYear: 20103617718420015594
90. Sturge J,Caley MP,Waxman J,Bone metastasis in prostate cancer: emerging therapeutic strategiesNat Rev Clin OncolYear: 2011835736821556025
91. Lombardo LJ,Lee FY,Chen P,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysJ Med ChemYear: 2004476658666115615512
92. Li J,Rix U,Fang B,et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancerNat Chem BiolYear: 2010629129920190765
93. Rice L,Lepler S,Pampo C,et al. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cellsClin Exp MetastasisYear: 20122913314222130962
94. Koreckij T,Nguyen H,Brown LG,et al. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysisBr J CancerYear: 200910126326819603032
95. Araujo JC,Mathew P,Armstrong AJ,et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 studyCancerYear: 2012118637121976132
96. Araujo JC,Trudel GC,Paliwal P,Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxelCancer Manag ResYear: 201362530 doi: 10.2147/CMAR.S41667. Epub;%2013 Mar 9.:25-30. 23516140
97. Twardowski PW,Beumer JH,Chen CS,et al. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapyAnticancer DrugsYear: 20132474375323652277
98. Yu EY,Wilding G,Posadas E,et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancerClin Cancer ResYear: 2009157421742819920114
99. Yu EY,Massard C,Gross ME,et al. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancerUrologyYear: 2011771166117121539969
100. Araujo JC,Trudel GC,Saad F,et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialLancet OncolYear: 2013
101. Dayyani F,Varkaris A,Araujo JC,et al. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancerProstateYear: 20137397998523371521
102. Dayyani F,Parikh NU,Varkaris AS,et al. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathwaysPLoS ONEYear: 20127e51189
103. Lara PN,Evans CP,Dasatinib and docetaxel in advanced prostate cancerLancet OncolYear: 2013
104. Evans CP,Lara PN Jr,Kung H,et al. Activity of the Src-kinase inhibitor AZD0530 in androgen-independent prostate cancer (AIPC): Pre-clinical rationale for a phase II trialJ Clin Oncol (ASCO Annual Meeting Proceedings)Year: 20062414542
105. Chang YM,Bai L,Liu S,et al. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530OncogeneYear: 2008
106. Yang JC,Bai L,Yap S,et al. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone modelMol Cancer TherYear: 201091629163720484016
107. Lara PN Jr,Longmate J,Evans CP,et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium studyAnticancer DrugsYear: 20092017918419396016
108. Boschelli DH,Wu B,Barrios Sosa AC,et al. Identification of 7-phenylaminothieno- [3,2-b]pyridine-6-carbonitriles as a new class of Src kinase inhibitorsJ Med ChemYear: 2004476666666815615514
109. Rabbani SA,Valentino ML,Arakelian A,et al. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasisMol Cancer TherYear: 201091147115720423991
110. Daud AI,Krishnamurthi SS,Saleh MN,et al. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumorsClin Cancer ResYear: 2012181092110022179664
111. Smith DC,Smith MR,Sweeney C,et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialJ Clin OncolYear: 20133141241923169517
112. Antonarakis ES,Heath EI,Posadas EM,et al. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancerCancer Chemother PharmacolYear: 20137188389223314737
113. Phatak SS,Zhang S,A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitorsPac Symp BiocomputYear: 2013294023424109
114. Mahajan K,Coppola D,Rawal B,et al. Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancerJ Biol ChemYear: 2012287221122212222566699
115. Hertz DL,McLeod HL,Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicityJ Hum GenetYear: 20135834635223677053
116. Dhanasekaran SM,Barrette TR,Ghosh D,et al. Delineation of prognostic biomarkers in prostate cancerNature JID - 0410462Year: 2001412822826
117. Yu YP,Landsittel D,Jing L,et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancyJ Clin OncolYear: 2004222790279915254046
118. Varambally S,Yu J,Laxman B,et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progressionCancer CellYear: 2005839340616286247
119. Tomlins SA,Mehra R,Rhodes DR,et al. Integrative molecular concept modeling of prostate cancer progressionNat GenetYear: 200739415117173048

Article Categories:
  • Review

Keywords: Src-family tyrosine kinases, Ack1, androgen receptor, prostate cancer, castration-recurrence..

Previous Document:  Modulation of Androgen Receptor by FOXA1 and FOXO1 Factors in Prostate Cancer.
Next Document:  Conversion of Androgen Receptor Signaling From a Growth Suppressor in Normal Prostate Epithelial Cel...